Immunotherapy for Infectious Diseases

94 Kunert and Katinger
72. Abbs IC, et al. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft
rejection is associated with diminished release of pro-inflammatory cytokines. Ther
Immunol 1994; 1:325–331.
73. Pereira H, et al. [Abciximab (ReoPro) in primary angioplasty]. Revi Port Cardiol 1998;
17:903–907.
74. Bailey SR, O’Leary E, Chilton R. Angioscopic evaluation of site-specific administration
of ReoPro [see comments]. Cathet Cardiovasc Diagn 1997; 42:181–184.
75. Blann AD, Miller JP, McCollum CN. von Willebrand factor and soluble E-selectin in the
prediction of cardiovascular disease progression in hyperlipidaemia. Atherosclerosis 1997;
132:151–156.
76. Steinitz M, et al. EB virus-induced B lymphocyte cell lines producing specific antibody.
Nature 1977; 269:420–422.
77. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined
specificity. Nature 1975; 256:495–497.
78. Ohlin M, et al. Human monoclonal antibodies against a recombinant HIV envelope antigen
produced by primary in vitro immunization. Characterization and epitope mapping.
Immunology 1989; 68:325–331.
79. Borrebaeck CA, Danielsson L, Müller SA. Human monoclonal antibodies produced by
primary in vitro immunization of peripheral blood lymphocytes. Proc Natl Acad Sci USA
1988; 85:3995–3999.
80. Zafiropoulos A, et al. Induction of antigen-specific isotype switching by in vitro immunization
of human naive B lymphocytes. J Immunol Methods 1997; 200;181–190.
81. Dueñas M, et al. In vitro immunization of naive human B cells yields high affinity
immunoglobulin G antibodies as illustrated by phage display. Immunology 1996; 89:1–7.
82. Fresen KO, Hausen H. Establishment of EBNA-expressing cell lines by infection of
Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV
strains. Int J Cancer 1976; 17:161–166.
83. Henderson E, et al. Efficiency of transformation of lymphocytes by Epstein-Barr virus.
Virology 1977; 76:152–163.
84. Katsuki T, et al. Identification of the target cells in human B lymphocytes for transformation
by Epstein-Barr virus. Virology 1977; 83:287–294.
85. Aman P, Ehlin-Henriksson B, Klein G. Epstein-Barr virus susceptibility of normal human
B lymphocyte populations. J Exp Med 1984; 159:208–220.
86. Tomita M, Tsong TY. Selective production of hybridoma cells: antigenic-based preselection
of B lymphocytes for electrofusion with myeloma cells. Biochim Biophys Acta
1990; 1055:199–206.
87. Shirahata S, Katakura Y, Teruya K. Cell hybridization, hybridomas, and human hybridomas.
Methods Cell Biol 1998; 57:111–145.
88. Jahn, S, et al. Strategies in the development of human monoclonal antibodies. Dev Biol
Stand 1990; 71:3–7.
89. Stanbridge EJ. Cell fusion, genetic cartography, and malignancy [letter]. Lancet 1976;
1:525.
90. Stanbridge EJ. Suppression of malignancy in human cells. Nature 1976; 260:17–20.
91. Kawahara H, et al. A new human fusion partner, HK-128, for making human-human
hybridomas producing monoclonal IgG antibodies. Cytotechnology 1990; 4:139–143.
92. Rioux JD, et al. Molecular characterization of the GM 4672 human lymphoblastoid cell
line and analysis of its use as a fusion partner in the generation of human-human hybridoma
autoantibodies. Hum Antibodies Hybridomas 1993; 4:107–114.
93. Hirata Y, Sugawara I. Characterization of mouse-human hybridoma as a useful fusion partner
for the establishment of mouse-human-human hybridoma secreting anti-tetanus toxoid
human monoclonal antibody of IgM or IgG class. Microbiol Immunol 1987;
31:231–245.